Related Experiment Videos
Digoxin
Eric J Eichhorn1, Mihai Gheorghiade
1Cardiac Catheterization Laboratory and Department of Internal Medicine, Dallas Veterans Administration Hospital and University of Texas Southwestern Medical Center, Dallas, TX, USA.
Progress in Cardiovascular Diseases
|May 15, 2002
Summary
Digoxin remains a valuable treatment for heart failure and atrial fibrillation, offering cost-effective rate control and inotropic support without increasing mortality. It is particularly useful for patients with systolic heart failure or atrial fibrillation unresponsive to other therapies.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Digitalis has been used for over 200 years.
- ACE inhibitors and beta-blockers offer proven survival benefits in heart failure.
- Digoxin is an established treatment for heart failure and atrial fibrillation.
Purpose of the Study:
- To evaluate the continued role of digitalis (digoxin) in managing heart failure and atrial fibrillation.
- To highlight the benefits of digoxin, including its low cost and safety profile.
- To define specific patient populations that may benefit from digoxin therapy.
Main Methods:
- Review of existing literature and clinical guidelines regarding digoxin use.
- Analysis of digoxin's efficacy and safety in heart failure and atrial fibrillation.
- Comparison of digoxin with other standard therapies like ACE inhibitors and beta-blockers.
Main Results:
- Digoxin is an inexpensive and well-tolerated oral inotrope that does not increase mortality in heart failure patients, especially at low doses.
- It remains a viable option for heart failure and atrial fibrillation management.
- Digoxin is particularly beneficial for patients with systolic heart failure or atrial fibrillation with uncontrolled symptoms despite other treatments.
Conclusions:
- Digoxin therapy is cost-effective and safe for specific patient groups.
- It plays a crucial role in managing heart failure and atrial fibrillation, especially for rate control.
- Digoxin should be considered for patients with systolic heart failure or atrial fibrillation who require additional therapeutic options.